These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 732257)

  • 41. The use of an angiotensin II antagonist (saralasin) as an adjunct during renal vein catheterization.
    Ibsen H; Giese J; Rabøl A; Kappelgaard AM
    Scand J Clin Lab Invest; 1980 Apr; 40(2):115-20. PubMed ID: 7020064
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Critical analysis of the saralasintest in the diagnosis of hypertension (author's transl)].
    Röckel A; Wernze H; Sabel B; Heidland A
    Klin Wochenschr; 1977 Jul; 55(13):651-6. PubMed ID: 895003
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pressor response to saralasin (1-sar-8-ala-angiotensin II) bolus injection in hypertensive patients.
    Waks UA; Maxwell MH; Marks L; Zawada ET; Kaufman JJ
    Circulation; 1978 Jun; 57(6):1165-70. PubMed ID: 639240
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Angiotensin blockade: its clinical significance.
    Streeten DH; Anderson GH; Dalakos TH
    Am J Med; 1976 May; 60(6):817-24. PubMed ID: 1020761
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Hemodynamics, renin and aldosterone following angiotensin II blockade and sodium chloride deficiency in hypertensive subjects].
    Beyer J; Liebau G; Steiner B; Schick K; Hayduk K
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():212-3. PubMed ID: 613577
    [No Abstract]   [Full Text] [Related]  

  • 46. Comparative study of an angiotensin-II analog and a converting enzyme inhibitor.
    Fagard RH; Amery AK; Lijnen PJ; Reybrouck TM
    Kidney Int; 1980 May; 17(5):647-53. PubMed ID: 6249956
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Saralasin-induced changes of blood pressure, renin and aldosterone in essential and renal hypertension (author's transl)].
    Beyer J; Liebau G; Steiner B; Hayduk K
    Klin Wochenschr; 1978 Sep; 56(17):859-64. PubMed ID: 713415
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diuretic therapy and response of essential hypertension to saralasin.
    Anderson GH; Dalakos TG; Elias A; Tomycz N; Streeten DH
    Ann Intern Med; 1977 Aug; 87(2):183-7. PubMed ID: 889199
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The influence of sar1 ala8 angiotensin II (saralasin) on plasma aldosterone in hypertensive patients.
    Donker AJ; van Hoogdalem P; Pratt JJ; Leenen FH
    Acta Med Scand; 1979; 205(3):207-12. PubMed ID: 425848
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of saralasin on plasma renin activity and arginine-vasopressin in hypertensive man.
    Arlart IP; Rosenthal J; Wagner H; Franz HE
    Proc Eur Dial Transplant Assoc; 1978; 15():412-7. PubMed ID: 740674
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypotensive effects of sodium volume depletion and 1-sar-8-ala-angiotensin II in relation to plasma renin in hypertensive patients.
    Fagard R; Amery A; Lijnen P; Reybrouck T
    Eur J Clin Pharmacol; 1977 Aug; 12(1):1-5. PubMed ID: 902672
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of renovascular hypertension: saralasin test versus renin determinations.
    Marks LS; Maxwell MH; Smith RB; Cahill PJ; Kaufman JJ
    J Urol; 1976 Oct; 116(4):406-9. PubMed ID: 1053323
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of the angiotensin II antagonist saralasin on blood pressure and plasma aldosterone in man in relation to the prevailing plasma angiotensin II concentration.
    Brown JJ; Brown WC; Fraser R; Lever AF; Morton JJ; Robertson JI; Rosei EA; Trust PM
    Prog Biochem Pharmacol; 1976; 12():230-41. PubMed ID: 1019166
    [TBL] [Abstract][Full Text] [Related]  

  • 54. False-negative saralasin responses in renovascular hypertension.
    Stokes GS; MacCarthy EP; Frost GW; Sheil AG
    Br J Urol; 1979 Apr; 51(2):92-9. PubMed ID: 465980
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effect of the angiotensin antagonist saralasin on blood pressure and hemodynamics in patients with terminal renal insufficiency].
    Tuma J; Beckerhoff R; Záruba K; Furrer J; Vetter W
    Schweiz Med Wochenschr; 1977 May; 107(20):704-9. PubMed ID: 867013
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Usefulness and limitations of saralasin, a partial competitive agonist of angioten II, for evaluating the renin and sodium factors in hypertensive patients.
    Case DB; Wallace JM; Keim HJ; Sealey JE; Laragh JH
    Am J Med; 1976 May; 60(6):825-36. PubMed ID: 1020762
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites.
    Arroyo V; Bosch J; Mauri M; Ribera F; Navarro-López F; Rodés J
    Eur J Clin Invest; 1981 Jun; 11(3):221-9. PubMed ID: 6791942
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Angiotensin II and renal hypertension in dog, rat and man: effect of converting enzyme inhibition.
    Atkinson AB; Brown JJ; Fraser R; Lever AF; Morton JJ; Riegger AJ; Robertson JI
    Clin Exp Hypertens (1978); 1980; 2(3-4):499-524. PubMed ID: 6253241
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Saralasin test as a diagnostic and prognostic aid in renovascular hypertensive patients subjected to renal operation.
    Poutasse EF; Gonzalez-Serva L; Wendelken JR; Franz JP
    J Urol; 1980 Mar; 123(3):306-10. PubMed ID: 6987415
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of an angiotensin antagonist (saralasin) on arterial pressure and plasma aldosterone in hemodialysis-resistant hypertensive patients.
    Mimran A; Shaldon S; Barjon P; Mion C
    Clin Nephrol; 1978 Feb; 9(2):63-7. PubMed ID: 639368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.